

Valeo Pharma's Steve Saviuk talks about the US\$40M non-dilutive financing from Sagard Healthcare Partners

In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.'s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and Director Steve Saviuk talks about closing a US\$40 million non-dilutive financing from Sagard Healthcare Partners and explains why Valeo is at "the right place at the right time with the right products."

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here to access InvestorChannel.com), Steve says that the proceeds from the financing will be utilized to fund acquisition of Canadian rights to 3 growing commercial stage drugs which will "more than double our current revenue run rate." Providing an update on Valeo's licensing agreement with Kaléo for the Canadian rights to ALLERJECT® he says, "We are relaunching it. Sales were \$4 million last year we expect sales to grow to about \$25 million." Steve also talks about adding ophthalmology as a new therapeutic focus for Valeo with the acquisition of the Canadian license rights to two innovative ophthalmic therapies from Novartis.

To access the full InvestorIntel interview, click here

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products

in Canada with a focus on Respiriology/Allergy, Ophthalmology and Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., [click here](#)

Disclaimer: *Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent

investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.